ALK
EstablishedALK gene rearrangements define a distinct, highly drug-responsive lung cancer subtype, generally mutually exclusive with other driver mutations.
ALK gene rearrangements create an abnormal, cancer-driving protein in a distinct subset of lung cancer patients, who respond very well to a specific class of pills. Newer generations of these drugs have gotten progressively better at also treating and preventing brain metastases, a common problem in this specific cancer subtype.
Anaplastic lymphoma kinase (ALK) gene rearrangements (most commonly EML4-ALK fusion) create a constitutively active fusion kinase driving tumor growth in a distinct subset of non-small cell lung cancer, occurring in roughly 3-5% of lung adenocarcinomas.
ALK-rearranged NSCLC is highly responsive to ALK inhibitors; this molecular subtype is generally mutually exclusive with EGFR, KRAS, and other major driver mutations, meaning a tumor typically has only one of these targetable alterations, not several.
Detected via fluorescence in situ hybridization (FISH, historically the gold standard), immunohistochemistry (increasingly used as a faster, cheaper alternative with good concordance), or NGS panel, which can simultaneously detect ALK alongside other driver alterations in one test.
Sequential-generation ALK inhibitors (crizotinib, then alectinib, then lorlatinib) have progressively improved both efficacy and central nervous system penetration, since brain metastases are a common and clinically significant site of progression in ALK-positive lung cancer.
Sequential ALK inhibitor generations have progressively improved control of brain metastases, a common site of disease progression.
- Translational Lung Cancer Research. (2023). EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: prevalence data on ALK and other NSCLC driver mutations.